S. 1173 119th Congress
Restore Protections for Dialysis Patients Act
Latest action, Mar 27, 2025: Read twice and referred to the Committee on Finance.
How the Senate voted
The Senate hasn't taken a roll call on this bill in the Congresses covered.
7 cosponsors
Sponsored by Bill Cassidy (Republican). Cosponsors by party, House members included:
- Democrats
- Republicans
- Independents
Cosponsors
2 D · 5 R
- Democrat
- Republican
- Independent
Referred to: Senate: Finance Committee
Who lobbied on it
Clients whose quarterly lobbying reports named it, each quarter.
The clients with the most reports naming it. A report's amount covers all of that client's lobbying in the quarter, not just this bill.
DAVITA INC
CAPITOL HILL CONSULTING GROUP
7 reports
7 reports
DAVITA, INC.
FEDERAL STREET STRATEGIES, LLC
7 reports
7 reports
7 reports
FRESENIUS MEDICAL CARE NORTH AMERICA
AVENUE SOLUTIONS
7 reports
KIDNEY CARE PARTNERS
FEDERAL HEALTH POLICY STRATEGIES
7 reports
U.S. RENAL CARE
JEFFREY J. KIMBELL & ASSOCIATES, INC.
7 reports
6 reports
DAVITA INC.
RED+BLUE STRATEGIES
6 reports
DIALYSIS PATIENT CITIZENS
KOUNTOUPES DENHAM CARR & REID, LLC
6 reports
6 reports
5 reports
AMERICAN NEPHROLOGY NURSES ASSOCIATION
VENABLE LLP
5 reports
All 25 of 34 clients
| Client | Lobbying firm | Reports | Reports totaling | From | To | Senate |
|---|---|---|---|---|---|---|
| DAVITA INC | CAPITOL HILL CONSULTING GROUP | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| DAVITA INC | 7 | $7.6M | Q1 2025 | Q3 2026 | yes | |
| DAVITA, INC. | FEDERAL STREET STRATEGIES, LLC | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| DIALYSIS PATIENT CITIZENS | 7 | $2.3M | Q1 2025 | Q3 2026 | yes | |
| FRESENIUS MEDICAL CARE NORTH AMERICA | 7 | $8.6M | Q1 2025 | Q3 2026 | yes | |
| FRESENIUS MEDICAL CARE NORTH AMERICA | AVENUE SOLUTIONS | 7 | $0 | Q1 2025 | Q3 2026 | yes |
| KIDNEY CARE PARTNERS | FEDERAL HEALTH POLICY STRATEGIES | 7 | $560K | Q1 2025 | Q3 2026 | yes |
| U.S. RENAL CARE | JEFFREY J. KIMBELL & ASSOCIATES, INC. | 7 | $350K | Q1 2025 | Q3 2026 | yes |
| AKEBIA THERAPEUTICS, INC. | 6 | $2.1M | Q1 2025 | Q2 2026 | yes | |
| AMERICAN ASSOCIATION OF NURSE PRACTITIONERS | 6 | $2.5M | Q4 2025 | Q3 2026 | yes | |
| DAVITA INC. | RED+BLUE STRATEGIES | 6 | $0 | Q4 2025 | Q3 2026 | yes |
| DIALYSIS PATIENT CITIZENS | KOUNTOUPES DENHAM CARR & REID, LLC | 6 | $0 | Q4 2025 | Q3 2026 | yes |
| SERVICE EMPLOYEES INTERNATIONAL UNION | NVG, LLC | 6 | $510K | Q4 2025 | Q3 2026 | yes |
| AMERICAN KIDNEY FUND | 5 | $1.0M | Q4 2025 | Q3 2026 | yes | |
| AMERICAN NEPHROLOGY NURSES ASSOCIATION | VENABLE LLP | 5 | $150K | Q4 2025 | Q3 2026 | yes |
| DAVITA, INC. | POWERS PYLES SUTTER & VERVILLE, P.C. | 5 | $0 | Q4 2025 | Q3 2026 | yes |
| KIDNEY CARE ACCESS COLAITION, INC. | CHECKMATE GOVERNMENT RELATIONS | 5 | $370K | Q4 2025 | Q2 2026 | yes |
| KIDNEY CARE PARTNERS | AVENUE SOLUTIONS | 5 | $380K | Q1 2025 | Q1 2026 | yes |
| DAVITA, INC | APOLLO GOVERNMENT RELATIONS (D/B/A APOLLO COUNSEL) | 4 | $0 | Q4 2025 | Q3 2026 | yes |
| KIDNEY CARE COUNCIL | RS GROUP CONSULTING LLC | 4 | $60K | Q4 2025 | Q3 2026 | yes |
| THE ROGOSIN INSTITUTE | THE FERRARO GROUP | 3 | $90K | Q1 2026 | Q3 2026 | yes |
| U.S. RENAL CARE | LESTER HEALTH LAW PLLC | 3 | $91K | Q1 2026 | Q3 2026 | yes |
| BOEING COMPANY | 2 | $5.5M | Q2 2026 | Q3 2026 | yes | |
| LOCKHEED MARTIN CORPORATION | 2 | $8.3M | Q1 2026 | Q2 2026 | yes | |
| RENAL HEALTHCARE ASSOCIATION | MEHLMAN CONSULTING, INC. | 2 | $140K | Q2 2026 | Q3 2026 | yes |